251. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M
Recent Results Cancer Res. 2003 .
PMID: 12790320 [PubMed - in process]
252. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells.
Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, Rosenecker J
J Biol Chem. 2003 Mar 28.
PMID: 12519756 [PubMed - in process]
253. Nonviral vector loaded collagen sponges for sustained gene delivery in vitro and in vivo.
Scherer F, Schillinger U, Putz U, Stemberger A, Plank C
J Gene Med. .
PMID: 12439855 [PubMed - in process]
254. Nonviral gene delivery to the lung with copolymer-protected and transferrin-modified polyethylenimine.
Rudolph C, Schillinger U, Plank C, Gessner A, Nicklaus P, Müller R, Rosenecker J
Biochim Biophys Acta. 2002 Oct 10.
PMID: 12383945 [PubMed - in process]
255. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V
FEBS Lett. 2002 Sep 25.
PMID: 12297307 [PubMed - in process]
256. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization.
Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN
J Immunol. 2002 Sep 1.
PMID: 12193708 [PubMed - in process]
257. O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes.
Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Krüger A, Schwaiger M, Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging. 2002 Aug .
PMID: 12173018 [PubMed - in process]
258. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA
Cancer Res. 2002 Aug 15.
PMID: 12183417 [PubMed - in process]
259. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.
Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, Gänsbacher B, Plank C
Gene Ther. 2002 Jan .
PMID: 11857068 [PubMed - in process]
260. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms.
Breiner KM, Schaller H, Knolle PA
Hepatology. 2001 Oct .
PMID: 11584379 [PubMed - in process]